ZUG, Switzerland–(BUSINESS WIRE)–Galderma today announced new data demonstrating nemolizumab’s long-term and increasing efficacy on skin lesions and other symptoms in prurigo nodularis through to week 52 in the OLYMPIA LTE study.1 Additionally, data from the ARCADIA 1 and 2 trials in atopic dermatitis indicate that the majority of patients maintained…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
